Gene expression analysis following RRP therapy INO-3107
Patients with HPV-6 and/or HPV-11 RRP, surgical interventions in the year preceding dosing, were administered 4 doses of INO-3107 by intramuscular (IM) injection followed by electroporation (EP). The primary endpoint was safety and tolerability.